- Report
- February 2025
- 200 Pages
Global
From €4255EUR$4,490USD£3,591GBP
- Report
- February 2025
- 200 Pages
Global
From €4255EUR$4,490USD£3,591GBP
- Report
- February 2025
- 200 Pages
Global
From €4255EUR$4,490USD£3,591GBP
- Report
- January 2025
- 135 Pages
Global
From €2842EUR$2,999USD£2,398GBP
- Report
- August 2024
- 136 Pages
Global
From €2842EUR$2,999USD£2,398GBP
- Report
- May 2024
- 137 Pages
Global
From €6158EUR$6,499USD£5,197GBP
- Report
- March 2025
- 450 Pages
Global
From €4738EUR$5,000USD£3,999GBP
- Clinical Trials
- March 2025
- 450 Pages
Global
From €4738EUR$5,000USD£3,999GBP
- Clinical Trials
- December 2024
- 180 Pages
Global
From €2369EUR$2,500USD£1,999GBP
- Clinical Trials
- June 2024
- 240 Pages
Global
From €2843EUR$3,000USD£2,399GBP
- Clinical Trials
- April 2024
- 150 Pages
Global
From €1895EUR$2,000USD£1,599GBP
- Clinical Trials
- April 2024
- 250 Pages
Global
From €2843EUR$3,000USD£2,399GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1421EUR$1,500USD£1,200GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1184EUR$1,250USD£1,000GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1184EUR$1,250USD£1,000GBP
- Report
- August 2024
- 150 Pages
Global
From €2643EUR$2,789USD£2,230GBP
- Report
- August 2024
- 150 Pages
Global
From €2643EUR$2,789USD£2,230GBP
- Report
- August 2024
- 150 Pages
Global
From €2643EUR$2,789USD£2,230GBP
- Report
- October 2024
- 200 Pages
Global
From €4690EUR$4,949USD£3,958GBP
- Report
- August 2024
- 150 Pages
Global
From €2643EUR$2,789USD£2,230GBP

Doxorubicin is an oncology drug used to treat a variety of cancers, including leukemia, lymphoma, and breast, ovarian, and bladder cancer. It is a type of anthracycline antibiotic, derived from Streptomyces peucetius, and works by interfering with the growth of cancer cells. It is administered intravenously, and is often used in combination with other drugs.
Doxorubicin is one of the most widely used chemotherapy drugs, and is often used in combination with other drugs to treat a variety of cancers. It is also used to treat Kaposi's sarcoma, a type of skin cancer. Side effects of doxorubicin include nausea, vomiting, hair loss, and an increased risk of infection.
The doxorubicin market is highly competitive, with many companies offering generic versions of the drug. Some of the major players in the market include Pfizer, Novartis, Merck, Bristol-Myers Squibb, and AstraZeneca. Show Less Read more